These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 21527517)

  • 1. A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway.
    Zheng Y; Qin H; Frank SJ; Deng L; Litchfield DW; Tefferi A; Pardanani A; Lin FT; Li J; Sha B; Benveniste EN
    Blood; 2011 Jul; 118(1):156-66. PubMed ID: 21527517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
    Pardanani A; Lasho T; Smith G; Burns CJ; Fantino E; Tefferi A
    Leukemia; 2009 Aug; 23(8):1441-5. PubMed ID: 19295546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
    Liu PC; Caulder E; Li J; Waeltz P; Margulis A; Wynn R; Becker-Pasha M; Li Y; Crowgey E; Hollis G; Haley P; Sparks RB; Combs AP; Rodgers JD; Burn TC; Vaddi K; Fridman JS
    Clin Cancer Res; 2009 Nov; 15(22):6891-900. PubMed ID: 19887489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAKs, Stats, and CK2?
    Carter-Su C; Argetsinger LS
    Blood; 2011 Jul; 118(1):5-6. PubMed ID: 21737607
    [No Abstract]   [Full Text] [Related]  

  • 5. JAK/STAT signal transduction: regulators and implication in hematological malignancies.
    Valentino L; Pierre J
    Biochem Pharmacol; 2006 Mar; 71(6):713-21. PubMed ID: 16426581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation.
    Aparicio-Siegmund S; Sommer J; Monhasery N; Schwanbeck R; Keil E; Finkenstädt D; Pfeffer K; Rose-John S; Scheller J; Garbers C
    Oncotarget; 2014 Apr; 5(8):2131-48. PubMed ID: 24742922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.
    Schwemmers S; Will B; Waller CF; Abdulkarim K; Johansson P; Andreasson B; Pahl HL
    Exp Hematol; 2007 Nov; 35(11):1695-703. PubMed ID: 17764814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
    Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
    PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
    Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
    Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent patents of gene mutation relative to JAK/STAT pathway and their implication in myeloproliferative diseases.
    Shi Y; Xu C
    Recent Pat DNA Gene Seq; 2008; 2(3):209-13. PubMed ID: 19075958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders.
    Levine RL; Wernig G
    Hematology Am Soc Hematol Educ Program; 2006; ():233-9, 510. PubMed ID: 17124066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAKs go nuclear: emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth.
    Zouein FA; Duhé RJ; Booz GW
    Growth Factors; 2011 Dec; 29(6):245-52. PubMed ID: 21892841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK/STAT signaling in hematological malignancies.
    Vainchenker W; Constantinescu SN
    Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
    Pardanani A; Tefferi A
    Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Negative regulation of the JAK/STAT: pathway implication in tumorigenesis].
    Espert L; Dusanter-Fourt I; Chelbi-Alix MK
    Bull Cancer; 2005 Oct; 92(10):845-57. PubMed ID: 16266868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
    Tibes R; Bogenberger JM; Geyer HL; Mesa RA
    Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
    Boissinot M; Cleyrat C; Vilaine M; Jacques Y; Corre I; Hermouet S
    Oncogene; 2011 Feb; 30(8):990-1001. PubMed ID: 21042281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.
    Iwamoto T; Senga T; Naito Y; Matsuda S; Miyake Y; Yoshimura A; Hamaguchi M
    Oncogene; 2000 Sep; 19(41):4795-801. PubMed ID: 11032030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The promise of Janus kinase inhibitors in the treatment of hematological malignancies.
    Senkevitch E; Durum S
    Cytokine; 2017 Oct; 98():33-41. PubMed ID: 28277287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.